Agios Pharmaceuticals, Inc. $AGIO Shares Sold by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP lessened its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 72.8% during the second quarter, Holdings Channel.com reports. The firm owned 56,900 shares of the biopharmaceutical company’s stock after selling 152,647 shares during the quarter. Seven Fleet Capital Management LP’s holdings in Agios Pharmaceuticals were worth $2,112,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in AGIO. Creative Planning raised its stake in shares of Agios Pharmaceuticals by 2.2% during the 3rd quarter. Creative Planning now owns 13,119 shares of the biopharmaceutical company’s stock worth $527,000 after buying an additional 280 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Agios Pharmaceuticals by 0.4% in the second quarter. The Manufacturers Life Insurance Company now owns 132,083 shares of the biopharmaceutical company’s stock valued at $4,393,000 after buying an additional 512 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in shares of Agios Pharmaceuticals by 3.4% in the third quarter. CANADA LIFE ASSURANCE Co now owns 20,325 shares of the biopharmaceutical company’s stock valued at $796,000 after buying an additional 662 shares in the last quarter. California State Teachers Retirement System grew its holdings in Agios Pharmaceuticals by 1.4% during the second quarter. California State Teachers Retirement System now owns 47,659 shares of the biopharmaceutical company’s stock worth $1,585,000 after acquiring an additional 671 shares during the period. Finally, Russell Investments Group Ltd. grew its holdings in Agios Pharmaceuticals by 8.6% during the second quarter. Russell Investments Group Ltd. now owns 9,292 shares of the biopharmaceutical company’s stock worth $309,000 after acquiring an additional 734 shares during the period.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. HC Wainwright raised their target price on Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Bank of America raised their price objective on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. TD Cowen upgraded shares of Agios Pharmaceuticals to a “strong-buy” rating in a research report on Monday. Royal Bank Of Canada increased their target price on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a report on Tuesday, July 7th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.25.

Agios Pharmaceuticals Stock Up 0.3%

NASDAQ:AGIO opened at $33.99 on Thursday. Agios Pharmaceuticals, Inc. has a 52-week low of $22.24 and a 52-week high of $46.00. The stock has a fifty day simple moving average of $35.91 and a 200-day simple moving average of $31.56. The company has a market capitalization of $2.03 billion, a PE ratio of -4.85 and a beta of 0.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. The business had revenue of $44.75 million during the quarter, compared to analyst estimates of $26.39 million. As a group, equities analysts anticipate that Agios Pharmaceuticals, Inc. will post -5.8 earnings per share for the current year.

Insider Activity

In other news, insider Sarah Gheuens sold 30,000 shares of the stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total value of $914,400.00. Following the sale, the insider directly owned 54,645 shares in the company, valued at $1,665,579.60. This represents a 35.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by company insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.